Dasatinib (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Dasatinib" in English language version.

refsWebsite

Global rank English rank

16nih.gov

4^th place

10doi.org

2^nd place

4fda.gov

447^th place

338^th place

3web.archive.org

1^st place

2semanticscholar.org

11^th place

8^th place

2bms.com

low place

1tga.gov.au

3,984^th place

2,622^nd place

1europa.eu

68^th place

117^th place

1drugs.com

399^th place

333^rd place

1handle.net

102^nd place

76^th place

1archive.today

14^th place

1nelm.nhs.uk

low place

1otsuka.co.jp

low place

1cenblog.org

low place

1com.bd

low place

archive.today

"NHS - Healthcare News". nelm.nhs.uk. Archived from the original on 5 May 2013. Retrieved 27 September 2011.

bms.com

news.bms.com

"FDA Approves U.S. Product Labeling Update for Sprycel (dasatinib) to Include Three-Year First-Line and Five-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase". Bristol-Myers Squibb (Press release). Archived from the original on 20 September 2018. Retrieved 23 April 2015.
"Bristol-Myers Squibb Announces Extension of U.S. Agreement for ABILIFY and Establishment of an Oncology Collaboration with Otsuka". Bristol-Myers Squibb (Press release). Archived from the original on 31 January 2015.

cenblog.org

Drahl C (16 January 2012). "How Jagabandhu Das made dasatinib possible". The Safety Zone blog. Chemical & Engineering News. Archived from the original on 10 December 2017. Retrieved 29 August 2016.

com.bd

medex.com.bd

"Dasanix". Medex. Retrieved 19 May 2021.

doi.org

Keating GM (January 2017). "Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia". Drugs. 77 (1): 85–96. doi:10.1007/s40265-016-0677-x. PMID 28032244. S2CID 207489056.
Olivieri A, Manzione L (June 2007). "Dasatinib: a new step in molecular target therapy". Annals of Oncology. 18 (Suppl 6): vi42 – vi46. doi:10.1093/annonc/mdm223. PMID 17591830.
Yurttaş NO, Eşkazan AE (2018). "Dasatinib-induced pulmonary arterial hypertension". British Journal of Clinical Pharmacology. 84 (5): 835–845. doi:10.1111/bcp.13508. PMC 5903230. PMID 29334406.
Özgür Yurttaş N, Eşkazan AE (May 2018). "Dasatinib-induced pulmonary arterial hypertension". British Journal of Clinical Pharmacology. 84 (5). Wiley: 835–845. doi:10.1111/bcp.13508. PMC 5903230. PMID 29334406.
Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, et al. (June 2006). "The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants". Cancer Research. 66 (11): 5790–7. doi:10.1158/0008-5472.CAN-05-4187. PMID 16740718.
Piscitani L, Sirolli V, Morroni M, Bonomini M (2020). "Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations". International Journal of Molecular Sciences. 21 (14): e4878. doi:10.3390/ijms21144878. PMC 7402330. PMID 32664269.
Braun TP, Eide CA, Druker BJ (2020). "Response and Resistance to BCR-ABL1-Targeted Therapies". Cancer Cell. 37 (4): 530–542. doi:10.1016/j.ccell.2020.03.006. PMC 7722523. PMID 32289275.
Cohen D (November 2014). "US trade rep is pressing Indian government to forbid production of generic cancer drug, consortium says". BMJ. 349: g6593. doi:10.1136/bmj.g6593. PMID 25370846. S2CID 206903723.
Kirkland JL, Tchkonia T (2020). "Senolytic drugs: from discovery to translation". Journal of Internal Medicine. 288 (5): 518–536. doi:10.1111/joim.13141. PMC 7405395. PMID 32686219.
Paez-Ribes M, González-Gualda E, Doherty GJ, Muñoz-Espín D (2019). "Targeting senescent cells in translational medicine". EMBO Molecular Medicine. 11 (12): e10234. doi:10.15252/emmm.201810234. PMC 6895604. PMID 31746100.

drugs.com

"Dasatinib". The American Society of Health-System Pharmacists. Retrieved 8 December 2017.

europa.eu

ema.europa.eu

"Sprycel EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 28 April 2020. This article incorporates text from this source, which is in the public domain.

fda.gov

"Sprycel (dasatinib) and risk of pulmonary arterial hypertension". U.S. Food and Drug Administration (FDA). 23 September 2011. Retrieved 28 April 2020. This article incorporates text from this source, which is in the public domain.
"2010 Notifications". U.S. Food and Drug Administration (FDA). 18 November 2010. Retrieved 28 April 2020. This article incorporates text from this source, which is in the public domain.
"FDA approves dasatinib for pediatric patients with CML". U.S. Food and Drug Administration (FDA). 9 November 2017. Retrieved 28 April 2020. This article incorporates text from this source, which is in the public domain.

accessdata.fda.gov

"Drug Approval Package: Sprycel (Dasatinib) NDA #021986 & 022072". U.S. Food and Drug Administration (FDA). 6 September 2006. Retrieved 28 April 2020.

handle.net

hdl.handle.net

World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

nelm.nhs.uk

"NHS - Healthcare News". nelm.nhs.uk. Archived from the original on 5 May 2013. Retrieved 27 September 2011.

nih.gov

pubmed.ncbi.nlm.nih.gov

Keating GM (January 2017). "Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia". Drugs. 77 (1): 85–96. doi:10.1007/s40265-016-0677-x. PMID 28032244. S2CID 207489056.
Olivieri A, Manzione L (June 2007). "Dasatinib: a new step in molecular target therapy". Annals of Oncology. 18 (Suppl 6): vi42 – vi46. doi:10.1093/annonc/mdm223. PMID 17591830.
Yurttaş NO, Eşkazan AE (2018). "Dasatinib-induced pulmonary arterial hypertension". British Journal of Clinical Pharmacology. 84 (5): 835–845. doi:10.1111/bcp.13508. PMC 5903230. PMID 29334406.
Özgür Yurttaş N, Eşkazan AE (May 2018). "Dasatinib-induced pulmonary arterial hypertension". British Journal of Clinical Pharmacology. 84 (5). Wiley: 835–845. doi:10.1111/bcp.13508. PMC 5903230. PMID 29334406.
Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, et al. (June 2006). "The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants". Cancer Research. 66 (11): 5790–7. doi:10.1158/0008-5472.CAN-05-4187. PMID 16740718.
Piscitani L, Sirolli V, Morroni M, Bonomini M (2020). "Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations". International Journal of Molecular Sciences. 21 (14): e4878. doi:10.3390/ijms21144878. PMC 7402330. PMID 32664269.
Braun TP, Eide CA, Druker BJ (2020). "Response and Resistance to BCR-ABL1-Targeted Therapies". Cancer Cell. 37 (4): 530–542. doi:10.1016/j.ccell.2020.03.006. PMC 7722523. PMID 32289275.
Cohen D (November 2014). "US trade rep is pressing Indian government to forbid production of generic cancer drug, consortium says". BMJ. 349: g6593. doi:10.1136/bmj.g6593. PMID 25370846. S2CID 206903723.
Kirkland JL, Tchkonia T (2020). "Senolytic drugs: from discovery to translation". Journal of Internal Medicine. 288 (5): 518–536. doi:10.1111/joim.13141. PMC 7405395. PMID 32686219.
Paez-Ribes M, González-Gualda E, Doherty GJ, Muñoz-Espín D (2019). "Targeting senescent cells in translational medicine". EMBO Molecular Medicine. 11 (12): e10234. doi:10.15252/emmm.201810234. PMC 6895604. PMID 31746100.

ncbi.nlm.nih.gov

Yurttaş NO, Eşkazan AE (2018). "Dasatinib-induced pulmonary arterial hypertension". British Journal of Clinical Pharmacology. 84 (5): 835–845. doi:10.1111/bcp.13508. PMC 5903230. PMID 29334406.
Özgür Yurttaş N, Eşkazan AE (May 2018). "Dasatinib-induced pulmonary arterial hypertension". British Journal of Clinical Pharmacology. 84 (5). Wiley: 835–845. doi:10.1111/bcp.13508. PMC 5903230. PMID 29334406.
Piscitani L, Sirolli V, Morroni M, Bonomini M (2020). "Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations". International Journal of Molecular Sciences. 21 (14): e4878. doi:10.3390/ijms21144878. PMC 7402330. PMID 32664269.
Braun TP, Eide CA, Druker BJ (2020). "Response and Resistance to BCR-ABL1-Targeted Therapies". Cancer Cell. 37 (4): 530–542. doi:10.1016/j.ccell.2020.03.006. PMC 7722523. PMID 32289275.
Kirkland JL, Tchkonia T (2020). "Senolytic drugs: from discovery to translation". Journal of Internal Medicine. 288 (5): 518–536. doi:10.1111/joim.13141. PMC 7405395. PMID 32686219.
Paez-Ribes M, González-Gualda E, Doherty GJ, Muñoz-Espín D (2019). "Targeting senescent cells in translational medicine". EMBO Molecular Medicine. 11 (12): e10234. doi:10.15252/emmm.201810234. PMC 6895604. PMID 31746100.

otsuka.co.jp

"Otsuka and Bristol-Myers Squibb Announce a Change in Contract Regarding Collaboration in Japan in the Oncology Therapy Area". 17 April 2023.

semanticscholar.org

api.semanticscholar.org

Keating GM (January 2017). "Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia". Drugs. 77 (1): 85–96. doi:10.1007/s40265-016-0677-x. PMID 28032244. S2CID 207489056.
Cohen D (November 2014). "US trade rep is pressing Indian government to forbid production of generic cancer drug, consortium says". BMJ. 349: g6593. doi:10.1136/bmj.g6593. PMID 25370846. S2CID 206903723.

tga.gov.au

ebs.tga.gov.au

"Sprycel (Dasatinib)" (PDF). Therapeutic Goods Administration (TGA). Retrieved 18 July 2020.

web.archive.org

"FDA Approves U.S. Product Labeling Update for Sprycel (dasatinib) to Include Three-Year First-Line and Five-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase". Bristol-Myers Squibb (Press release). Archived from the original on 20 September 2018. Retrieved 23 April 2015.
"Bristol-Myers Squibb Announces Extension of U.S. Agreement for ABILIFY and Establishment of an Oncology Collaboration with Otsuka". Bristol-Myers Squibb (Press release). Archived from the original on 31 January 2015.
Drahl C (16 January 2012). "How Jagabandhu Das made dasatinib possible". The Safety Zone blog. Chemical & Engineering News. Archived from the original on 10 December 2017. Retrieved 29 August 2016.